AR078002A1 - Uso de catepsina h para identificar compuestos que modulan el dolor neuropatico - Google Patents

Uso de catepsina h para identificar compuestos que modulan el dolor neuropatico

Info

Publication number
AR078002A1
AR078002A1 ARP100103179A ARP100103179A AR078002A1 AR 078002 A1 AR078002 A1 AR 078002A1 AR P100103179 A ARP100103179 A AR P100103179A AR P100103179 A ARP100103179 A AR P100103179A AR 078002 A1 AR078002 A1 AR 078002A1
Authority
AR
Argentina
Prior art keywords
cathepsin
activity
neuropathic pain
catepsin
compound
Prior art date
Application number
ARP100103179A
Other languages
English (en)
Original Assignee
Sanofi Aventis
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Sanofi Aventis filed Critical Sanofi Aventis
Publication of AR078002A1 publication Critical patent/AR078002A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N9/00—Enzymes; Proenzymes; Compositions thereof; Processes for preparing, activating, inhibiting, separating or purifying enzymes
    • C12N9/14—Hydrolases (3)
    • C12N9/48—Hydrolases (3) acting on peptide bonds (3.4)
    • C12N9/50—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25)
    • C12N9/52—Proteinases, e.g. Endopeptidases (3.4.21-3.4.25) derived from bacteria or Archaea
    • A—HUMAN NECESSITIES
    • A01—AGRICULTURE; FORESTRY; ANIMAL HUSBANDRY; HUNTING; TRAPPING; FISHING
    • A01K—ANIMAL HUSBANDRY; AVICULTURE; APICULTURE; PISCICULTURE; FISHING; REARING OR BREEDING ANIMALS, NOT OTHERWISE PROVIDED FOR; NEW BREEDS OF ANIMALS
    • A01K67/00—Rearing or breeding animals, not otherwise provided for; New or modified breeds of animals
    • A01K67/027—New or modified breeds of vertebrates
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
    • C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
    • C12Q1/34—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase
    • C12Q1/37—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving hydrolase involving peptidase or proteinase
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/53—Immunoassay; Biospecific binding assay; Materials therefor
    • G01N33/573—Immunoassay; Biospecific binding assay; Materials therefor for enzymes or isoenzymes
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
    • G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
    • G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
    • G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
    • G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
    • G01N33/6896—Neurological disorders, e.g. Alzheimer's disease
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
    • G01N2333/90—Enzymes; Proenzymes
    • G01N2333/914—Hydrolases (3)
    • G01N2333/948—Hydrolases (3) acting on peptide bonds (3.4)
    • G01N2333/95—Proteinases, i.e. endopeptidases (3.4.21-3.4.99)
    • G01N2333/964—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue
    • G01N2333/96425—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals
    • G01N2333/96427—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general
    • G01N2333/9643—Proteinases, i.e. endopeptidases (3.4.21-3.4.99) derived from animal tissue from mammals in general with EC number
    • G01N2333/96466—Cysteine endopeptidases (3.4.22)
    • G—PHYSICS
    • G01—MEASURING; TESTING
    • G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
    • G01N2800/00—Detection or diagnosis of diseases
    • G01N2800/28—Neurological disorders
    • G01N2800/2842—Pain, e.g. neuropathic pain, psychogenic pain

Landscapes

  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Chemical & Material Sciences (AREA)
  • Immunology (AREA)
  • Biomedical Technology (AREA)
  • Molecular Biology (AREA)
  • Organic Chemistry (AREA)
  • Hematology (AREA)
  • Urology & Nephrology (AREA)
  • General Health & Medical Sciences (AREA)
  • Biochemistry (AREA)
  • Biotechnology (AREA)
  • Microbiology (AREA)
  • Physics & Mathematics (AREA)
  • Zoology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Medicinal Chemistry (AREA)
  • Analytical Chemistry (AREA)
  • Wood Science & Technology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • General Physics & Mathematics (AREA)
  • Food Science & Technology (AREA)
  • Pathology (AREA)
  • Cell Biology (AREA)
  • Genetics & Genomics (AREA)
  • General Engineering & Computer Science (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Environmental Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Public Health (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Biodiversity & Conservation Biology (AREA)
  • Animal Husbandry (AREA)

Abstract

Métodos para seleccionar agentes farmacéuticos, para diagnosticar la susceptibilidad al dolor y para el tratamiento del dolor. Reivindicacion 11: Un método para identificar o analizar compuestos que modulan y/o previenen el dolor neuropático, que comprende las etapas de f) proporcionar al menos dos muestras; g) poner en contacto una muestra que contiene Catepsina H o un fragmento funcional o derivado de la misma con un compuesto, h) determinar la actividad de la Catepsina H en presencia del compuesto, i) determinar la actividad de Catepsina H en ausencia del compuesto, y j) comparar la actividad de Catepsina H de acuerdo con c) con la actividad de acuerdo con d).
ARP100103179A 2009-08-31 2010-08-31 Uso de catepsina h para identificar compuestos que modulan el dolor neuropatico AR078002A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
EP09290659A EP2293072A1 (en) 2009-08-31 2009-08-31 Use of cathepsin H

Publications (1)

Publication Number Publication Date
AR078002A1 true AR078002A1 (es) 2011-10-05

Family

ID=42150608

Family Applications (1)

Application Number Title Priority Date Filing Date
ARP100103179A AR078002A1 (es) 2009-08-31 2010-08-31 Uso de catepsina h para identificar compuestos que modulan el dolor neuropatico

Country Status (16)

Country Link
US (1) US20120252878A1 (es)
EP (2) EP2293072A1 (es)
JP (2) JP5980116B2 (es)
KR (1) KR20120073261A (es)
CN (1) CN102713631B (es)
AR (1) AR078002A1 (es)
AU (1) AU2010288468B2 (es)
BR (1) BR112012004450A2 (es)
CA (1) CA2772004A1 (es)
IL (1) IL218326A (es)
MX (1) MX346460B (es)
MY (1) MY179784A (es)
RU (1) RU2574005C2 (es)
SG (2) SG178929A1 (es)
TW (1) TW201113033A (es)
WO (1) WO2011023786A1 (es)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EP2532755A1 (en) * 2011-06-10 2012-12-12 Sanofi-Aventis Methods and uses based on Slfn2 expression and relating to the identification and profiling of compounds for use in the treatment or prevention of pain
CN105969904B (zh) * 2016-07-27 2019-10-11 北京泱深生物信息技术有限公司 多发性骨髓瘤生物标志物

Family Cites Families (21)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
GB8308235D0 (en) 1983-03-25 1983-05-05 Celltech Ltd Polypeptides
US4816567A (en) 1983-04-08 1989-03-28 Genentech, Inc. Recombinant immunoglobin preparations
DE3785186T2 (de) 1986-09-02 1993-07-15 Enzon Lab Inc Bindungsmolekuele mit einzelpolypeptidkette.
ES2052027T5 (es) 1988-11-11 2005-04-16 Medical Research Council Clonacion de secuencias de dominio variable de inmunoglobulina.
US6300129B1 (en) 1990-08-29 2001-10-09 Genpharm International Transgenic non-human animals for producing heterologous antibodies
AU665025B2 (en) 1991-09-23 1995-12-14 Cambridge Antibody Technology Limited Production of chimeric antibodies - a combinatorial approach
FR2739031B1 (fr) 1995-09-27 1997-11-21 Lhd Lab Hygiene Dietetique Systeme matriciel transdermique d'administration d'un oestrogene et/ou d'un progestatif a base de copolymere styrene-isoprene-styrene, procede de preparation et utilisation en therapeutique
US5736154A (en) 1996-03-11 1998-04-07 Fuisz Technologies Ltd. Transdermal delivery system
NZ332033A (en) 1996-03-25 1999-09-29 Lohmann Therapie Syst Lts Transdermal therapeutic system (tts) with small application-area thickness and great flexibility, and production process
AUPO379596A0 (en) 1996-11-22 1996-12-19 Soltec Research Pty Ltd Percutaneous delivery system
US20040055022A1 (en) * 2000-02-08 2004-03-18 Nick Cheng Compositions and methods for screening therapeutic agents
US20030138803A1 (en) * 2001-07-27 2003-07-24 Brooksbank Robert Alan Identification and use of molecules implicated in pain
US20030148314A1 (en) * 2001-08-01 2003-08-07 Millennium Pharmaceuticals, Inc. Compositions, kits, and methods for identification, assessment, prevention, and therapy of colon cancer
US20060241074A1 (en) * 2001-08-14 2006-10-26 The General Hospital Corporation Methods for treatment of pain
US20030144234A1 (en) * 2001-08-30 2003-07-31 Buxton Francis Paul Methods for the treatment of chronic pain and compositions therefor
US20030212003A1 (en) * 2002-02-14 2003-11-13 Hermann Lubbert Cathepsin Y for the development of a medicament for the treatment of pain
US20070015271A1 (en) * 2002-04-04 2007-01-18 Rosen Craig A Human secreted proteins
US6897240B2 (en) * 2002-05-08 2005-05-24 The Regents Of The University Of California Thio semicarbazone and semicarbazone inhibitors of cysteine proteases and methods of their use
US7261882B2 (en) * 2003-06-23 2007-08-28 Reagents Of The University Of Colorado Methods for treating neuropathic pain by administering IL-10 polypeptides
AU2005245785B2 (en) * 2004-04-15 2011-04-07 Banyan Biomarkers Inc. Proteolytic markers as diagnostic biomarkers for cancer, organ injury and muscle rehabilitation/exercise overtraining
EP2105742A1 (en) * 2008-03-26 2009-09-30 Sanofi-Aventis Use of cathepsin C

Also Published As

Publication number Publication date
MY179784A (en) 2020-11-13
AU2010288468B2 (en) 2015-04-30
MX2012002627A (es) 2012-05-08
MX346460B (es) 2017-03-22
TW201113033A (en) 2011-04-16
CN102713631B (zh) 2015-12-09
SG178929A1 (en) 2012-04-27
WO2011023786A1 (en) 2011-03-03
AU2010288468A1 (en) 2012-03-15
IL218326A (en) 2015-10-29
RU2574005C2 (ru) 2016-01-27
KR20120073261A (ko) 2012-07-04
CA2772004A1 (en) 2011-03-03
EP2473855A1 (en) 2012-07-11
CN102713631A (zh) 2012-10-03
JP2013502912A (ja) 2013-01-31
SG10201507228XA (en) 2015-10-29
EP2293072A1 (en) 2011-03-09
RU2012112539A (ru) 2013-10-10
IL218326A0 (en) 2012-04-30
US20120252878A1 (en) 2012-10-04
JP2016104013A (ja) 2016-06-09
JP5980116B2 (ja) 2016-08-31
BR112012004450A2 (pt) 2016-11-16

Similar Documents

Publication Publication Date Title
ES2572372T3 (es) Método de diagnóstico de enfermedades neurodegenerativas basado en la medición de los niveles o de la actividad de SIRT1
CR20110567A (es) Dispositivos para diagnostico y metodos relacionados
AR071034A1 (es) Uso de la catepsina c en el diagnostico de susceptibilidad al dolor y para el tratamiento del dolor
BR9914648A (pt) Processo para monitorar ação medicamentosa deinibidor de proteasoma
CL2011002228A1 (es) Aparato para el analisis integrado de acidos nucleicos en tiempo real, y metodo de detecicion de dichas moleculas.
GB2463401B (en) Characterizing prostate disorders by analysis of microvesicles
ATE503846T1 (de) Verfahren zur diagnose eines ovarialkarzinoms
BRPI0613478B8 (pt) dispositivo para análise quantitativa de um perfil de metabólito
EA201400491A1 (ru) Сопровождающая диагностика для терапии с антигиалуроновым агентом и способы ее применения
BRPI0915619A2 (pt) métodos para determinar uma probabilidade de que um sujeito tenha contribuído com material genético para amostra de teste de material genético, para caracterizar amostra de teste de material genético e para determinar se uma pessoa de interesse contribuiu com material genético para uma amostra de teste de material genético, kit para análise de amostra de teste de material genético e sistema para determinar se um sujeito contribuiu com material genético para uma amostra
PE20141450A1 (es) Ensayo de lisiloxidasa-homologo 2 y metodos de uso del mismo
EA201000734A1 (ru) Способ и аппарат для мониторинга пространственного образования фибринового сгустка
BR112019006879A2 (pt) sistema de análise e método para testagem de uma amostra
AR091783A1 (es) Un metodo para elaborar un indice de diversidad e indice de viabilidad de microorganismos en muestras de proceso
ATE474228T1 (de) Reagenz für hämoglobinabbau
DK2185939T3 (da) Engangsanalyseudstyr med mikroprocessor
BR112018010764A2 (pt) método para detectar atividade bacteriana em uma amostra biológica e unidade de detecção correspondente
WO2019066572A3 (en) Method and device for analyzing target analyte in sample
WO2015054700A3 (en) Biomarkers for predicting risk of acute ischemic stroke and methods of use thereof
AR076113A1 (es) Metodo o sistema que usa biomarcadores para el seguimiento de un tratamiento
MX2009001070A (es) Uso de proteina con actividad inhibidora de melanoma (mia) como un indicador temprano para la respuesta terapeutica en melanoma.
AR059361A1 (es) Dispositivo y metodos para detectar y cuantificar uno o mas agentes objetivos
PE20080908A1 (es) Agonistas lxr para el tratamiento de osteoartritis
WO2006066917A3 (en) Use of asc as a marker for colorectal cancer
AR078002A1 (es) Uso de catepsina h para identificar compuestos que modulan el dolor neuropatico

Legal Events

Date Code Title Description
FB Suspension of granting procedure